Role of fibulin-3 in the diagnosis of malignant mesothelioma

Agha, Mohammed A.; El-Habashy, Mahmoud M.; El-Shazly, Rania A.

doi:10.1016/j.ejcdt.2013.10.004

Cited by 22 publications

(27 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study has confirmed the role of serum and pleural fibulin-3 in the diagnosis of pleural mesothelioma and its role in differentiating between malignant and benign pleural diseases (Agha et al, 2014). This study showed correlation between serum and pleural fibulin-3.…”

Section: Figure 2 Multivariate Analysis Results For Advanced Stage Ssupporting

confidence: 56%

“…Promising new biomarker studies are ongoing. In regards to diagnosis of MM, few studies have researched fibulin-3 in serum or plasma and in pleural effusions in order to distinguish mesothelioma patients from either healthy controls or patients with benign disease (Pass et al, 2012;Agha et al, 2014). Pass et al (2012) were the first to report that that they measured plasma fibulin-3 levels (from 92 patients with mesothelioma, 136 asbestos-exposed persons without cancer, 93 patients with effusions not due to mesothelioma, and 43 healthy controls), effusions (from 74 patients with mesothelioma, 39 with benign effusions, and 54 with malignant effusions not due to mesothelioma), or both (Pass et al, 2012).…”

Section: Figure 2 Multivariate Analysis Results For Advanced Stage Smentioning

confidence: 99%

“…Fibulin-3 is expressed in condensing mesenchyme, giving rise to bony and cartilaginous structures (Zhang and Marmorstein, 2010). In previous studies, different types of cancer have been associated with fibulin-3, such as brain, hepatocellular, prostate, colorectal, and lung (Hu et al, 2009;Nomoto et al, 2010;Kim et al, 2011;Tong et al, 2011;Kim et al, 2012) however, there are few studies pertaining to the association with MM (Pass et al, 2012;Agha et al, 2014;Creaney et al, 2014). In these studies, levels of fibulin-3 investigated in patients with occupational asbestos exposure.…”

Section: Fibulin-3 As a Diagnostic Biomarker In Patients With Malignamentioning

confidence: 99%

See 2 more Smart Citations

Fibulin-3 as a Diagnostic Biomarker in Patients with Malignant Mesothelioma

Kaya

Demir²,

Taylan³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: New tumour biomarkers are being intensely investigated for malignant mesothelioma (MM). Fibulin-3 is produced in MM but its role remains uncertain. The aim of this study was to evaluate the validity of measuring serum fibulin-3 in the diagnosis and prognosis of MM. Materials and Methods: This prospective study was performed on 43 patients and 40 healthy controls who were admitted to our hospital between January 2012 and January 2014. Data from MM patients, including demographic and clinical features, routine laboratory data, levels of serum fibulin-3, and treatment outcomes were defined as potential prognostic factors. The receiver operating characteristic (ROC) curve for fibulin-3 was used to detect the cut-off value with highest sensitivity and specificity. Univariate survival analysis was performed using the Kaplan-Meier method in patients with MM. Afterwards, the possible factors identified with univariate analyses were entered into the cox regression analysis. Results: Our results revealed that patients with MM had significantly higher serum levels of fibulin-3 than controls. The results showed that the best cut-off point was 36.6 ng/ml with an AUC (area under the curve)=0.976, sensitivity=93.0% and specificity=90.0. In our study, the initial significant poor prognostic factors were advanced stage, high white blood cell count, high platelet count, high C-reactive protein (p<0.05 for each variable). Later, according to multivariate analysis the results showed only advanced stage as significant parameter (p=0.040). Conclusions: We determined that real use for serum fibulin-3 was not for prognosis but for diagnosis in MM. Also advanced stage was associated with poor MM prognosis.

show abstract

Section: Figure 2 Multivariate Analysis Results For Advanced Stage Ssupporting

confidence: 56%

Section: Figure 2 Multivariate Analysis Results For Advanced Stage Smentioning

confidence: 99%

Section: Fibulin-3 As a Diagnostic Biomarker In Patients With Malignamentioning

confidence: 99%

See 1 more Smart Citation

Fibulin-3 as a Diagnostic Biomarker in Patients with Malignant Mesothelioma

Kaya

Demir²,

Taylan³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Using independent, internally determined threshold values, they found that serum fibulin-3 had 100% sensitivity for mesothelioma at 78% specificity relative to nonmalignant effusions, and 88% sensitivity for mesothelioma at 82% specificity relative to malignant effusions owing to metastatic disease. When effusion samples were examined, sensitivity was 88% and 72% for mesothelioma compared with nonmalignant and metastatic cancer controls respectively (at a similar specificity of approximately 80%) [34]. Data for the different sample sets were not combined and results could not be compared with previous studies, although appear similar to the original Pass et al's study.…”

Section: Fibulin-3mentioning

confidence: 85%

Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma

Creaney

Dick

Robinson

2015

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

show abstract

“…In a study of 153 patients (82 with MPM), Creaney et al 14 reported a sensitivity of 22% (at 95% specificity) at the same 52 ng/mL cut-point and an AUC of 0.671 (0.606 to 0.732), which was significantly inferior to mesothelin measured in the same patients (sensitivity 56% (at 95% specificity); AUC 0.816 (0.755 to 0.867)) at a 2.5 nM threshold). In a small Egyptian study using an unspecified fibulin-3 assay and internally defined cut-points, Agha et al 34 reported 100% sensitivity/78% specificity in differentiating MPM cases (n=25) from non-malignant pleural disease (n=9), and 88% sensitivity/82% specificity in differentiating MPM from secondary pleural malignancies (n=11). No combined sensitivity was reported.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study

et al. 2016

View full text Add to dashboard Cite

IntroductionMalignant pleural mesothelioma (MPM) is an asbestos-related cancer, which is difficult to diagnose. Thoracoscopy is frequently required but is not widely available. An accurate, non-invasive diagnostic biomarker would allow early specialist referral, limit diagnostic delays and maximise clinical trial access. Current markers offer insufficient sensitivity and are not routinely used. The SOMAmer proteomic classifier and fibulin-3 have recently demonstrated sensitivity and specificity exceeding 90% in retrospective studies. DIAPHRAGM (Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma) is a suitably powered, multicentre, prospective observational study designed to determine whether these markers provide clinically useful diagnostic and prognostic information.Methods and analysisSerum and plasma (for SOMAscan and fibulin-3, respectively) will be collected at presentation, prior to pleural biopsy/pleurodesis, from 83 to 120 patients with MPM, at least 480 patients with non-MPM pleural disease and 109 asbestos-exposed controls. Final numbers of MPM/non-MPM cases will depend on the incidence of MPM in the study population (estimated at 13–20%). Identical sampling and storage protocols will be used in 22 recruiting centres and histological confirmation sought in all cases. Markers will be measured using the SOMAscan proteomic assay (SomaLogic) and a commercially available fibulin-3 ELISA (USCN Life Science). The SE in the estimated sensitivity and specificity will be <5% for each marker and their performance will be compared with serum mesothelin. Blood levels will be compared with paired pleural fluid levels and MPM tumour volume (using MRI) in a nested substudy. The prognostic value of each marker will be assessed and a large bioresource created.Ethics and disseminationThe study has been approved by the West of Scotland Research Ethics Committee (Ref: 13/WS/0240). A Trial Management Group meets on a monthly basis. Results will be published in peer-reviewed journals, presented at international meetings and disseminated to patient groups.Trial registration numberISRCTN10079972, Pre-results.

show abstract

Role of fibulin-3 in the diagnosis of malignant mesothelioma

Cited by 22 publications

References 18 publications

Fibulin-3 as a Diagnostic Biomarker in Patients with Malignant Mesothelioma

Fibulin-3 as a Diagnostic Biomarker in Patients with Malignant Mesothelioma

Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma

Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study

Contact Info

Product

Resources

About